Prednisone NDC 60687-145

NDC codes

FDA NDC Directory

Product NDC (as listed)60687-145Labeler and product segments. Claims need a package NDC.

Product NDC at billing width60687-0145Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
60687-145-01	60687014501	100 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-145-01) / 1 TABLET in 1 BLISTER PACK (60687-145-11)Marketed from Oct 5, 2015

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Prednisone
Generic name (nonproprietary): prednisone
Active ingredients: Prednisone — 20 mg/1
Dosage form: Tablet
Route: Oral
Labeler: American Health Packaging
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 040392
Marketing start: Oct 5, 2015
Marketing end: Mar 31, 2027
Other FDA classes: Corticosteroid Hormone Receptor Agonists (Mechanism)
Identifiers: Product ID 60687-145_46a0c9d3-8ce8-d59e-e063-6294a90ab258SPL ID 46a0c9d3-8ce8-d59e-e063-6294a90ab258SPL set ID a0e8d1a2-8c82-4dc0-8c2f-9da84382f34eRxCUI 198145, 312615, 312617UNII VB0R961HZT
Pharmacologic class: Corticosteroid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N460687014501 followed by a unit qualifier and the quantity

Package 60687-0145-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 23, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE PredniSONE Tablets are indicated in the following conditions: Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may r…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 040392

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 040392
Product	Strength	Form · route	Labeler	Product NDC
Prednisone	Prednisone 20 mg/1	TabletOral	Par Health USA, LLC	0603-5339
Prednisone	Prednisone 20 mg/1	TabletOral	Cardinal Health 107, LLC	55154-2147